CNTN

Canton Strategic Holdings, Inc. (CNTN) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Canton Strategic Holdings, Inc. (formerly Tharimmune, Inc.) has executed a strategic pivot from a clinical-stage biotechnology company to a dual-segment entity focusing on a digital asset treasury strategy centered on Canton Coin (CC) and the Canton Network, while maintaining its legacy biotechnology operations through its subsidiary, Gravitas Life Sciences, Inc. The company is classified as a smaller reporting company and an emerging growth company.

Key Financial Metrics

Cash Flow Highlights: Net cash used in operating activities was $7.6 million. Net cash used in investing activities was $54.8 million (purchase of digital assets). Net cash provided by financing activities was $87.0 million, driven by equity offerings.

Material Changes vs. Prior Period

• Strategic Pivot: The company launched a digital asset treasury strategy in November 2025, resulting in the acquisition of over 3.6 billion Canton Coins (CC) valued at $541.6 million as of March 31, 2026.
• Expense Surge: General and administrative expenses increased by $34.6 million (1,174%) to $36.6 million. This was primarily driven by $32.3 million in stock-based compensation related to strategic advisor warrants and other equity issuances.
• Capital Raising: The company raised significant capital through a private placement in late 2025, a registered direct offering in January 2026 ($52.7 million net), and at-the-market (ATM) offerings ($35 million net in Q1).
• Biotech Operations: Research and development expenses decreased by 55% to $0.3 million as the company shifted focus to the digital asset strategy.
• Valuation Impact: The company recorded an unrealized loss of $15.0 million on its digital asset holdings due to the decline in the reference price of CC relative to its weighted average cost.

Guidance, Outlook, and Risks

Management Commentary: Management believes the company has sufficient liquidity to fund operations through at least March 2027. The primary focus remains on building the digital asset treasury, operating as a Super Validator on the Canton Network, and supporting the ecosystem. The legacy biotech segment continues to advance its lead candidate, GV104, toward a 505(b)(2) NDA submission.

Risks and Contingencies:

• Digital Asset Volatility: The company's financial position is highly correlated with the price of Canton Coin. Significant price fluctuations could materially impact the balance sheet and net income.
• Going Concern: While liquidity is currently strong, the company relies on future financing and the success of its digital asset strategy to achieve profitability.
• Regulatory Uncertainty: Risks exist regarding the regulatory environment for digital assets and the approval of biotech product candidates.
• Related Party Transactions: The company purchased $47.2 million of CC from an affiliate liquidity provider controlled by a significant shareholder during the quarter.

Investor Verification Checklist

• Digital Asset Valuation: Verify the methodology used to determine the fair value of Canton Coin and the specific market data sources cited.
• Stock-Based Compensation: Review the details of the $32.3 million stock-based compensation expense, specifically the valuation of strategic advisor warrants and the terms of the 2023 Omnibus Incentive Plan amendments.
• Related Party Transactions: Scrutinize the terms of the $47.2 million CC purchase from the affiliate liquidity provider to ensure arm's length pricing.
• Liquidity Runway: Confirm the projected cash burn rate and the sufficiency of the $41.5 million cash balance against future operational and treasury acquisition costs.
• Biotech Progress: Monitor the status of the GV104 NDA submission timeline and any regulatory feedback from the FDA.